Abstract
Cilengitide, a cyclic RGD pentapeptide, is currently in clinical phase III for treatment of glioblastomas and in phase II for several other tumors. This drug is the first anti-angiogenic small molecule targeting the integrins αvβ3, αvβ5 and α5β1. It was developed by us in the early 90s by a novel procedure, the spatial screening. This strategy resulted in c(RGDfV), the first superactive αvβ3 inhibitor (100 to 1000 times increased activity over the linear reference peptides), which in addition exhibited high selectivity against the platelet receptor αIIbβ3. This cyclic peptide was later modified by N-methylation of one peptide bond to yield an even greater antagonistic activity in c(RGDf(NMe)V). This peptide was then dubbed Cilengitide and is currently developed as drug by the company Merck-Serono (Germany). This article describes the chemical development of Cilengitide, the biochemical background of its activity and a short review about the present clinical trials. The positive anti-angiogenic effects in cancer treatment can be further increased by combination with “classical” anti-cancer therapies. Several clinical trials in this direction are under investigation.
Keywords: RGD peptides, integrin antagonists, glioblastoma, N-methylation, conformational restriction, cyclization, Anti-Angiogenic, RGD, ECM, CAM, Angiogenesis, Tumor Vasculature, IMD, NMR, VEGFs, Cilengitide, NSCLC, radio-chemotherapy, ITH, GBM
Anti-Cancer Agents in Medicinal Chemistry
Title: Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
Volume: 10 Issue: 10
Author(s): Carlos Mas-Moruno, Florian Rechenmacher and Horst Kessler
Affiliation:
Keywords: RGD peptides, integrin antagonists, glioblastoma, N-methylation, conformational restriction, cyclization, Anti-Angiogenic, RGD, ECM, CAM, Angiogenesis, Tumor Vasculature, IMD, NMR, VEGFs, Cilengitide, NSCLC, radio-chemotherapy, ITH, GBM
Abstract: Cilengitide, a cyclic RGD pentapeptide, is currently in clinical phase III for treatment of glioblastomas and in phase II for several other tumors. This drug is the first anti-angiogenic small molecule targeting the integrins αvβ3, αvβ5 and α5β1. It was developed by us in the early 90s by a novel procedure, the spatial screening. This strategy resulted in c(RGDfV), the first superactive αvβ3 inhibitor (100 to 1000 times increased activity over the linear reference peptides), which in addition exhibited high selectivity against the platelet receptor αIIbβ3. This cyclic peptide was later modified by N-methylation of one peptide bond to yield an even greater antagonistic activity in c(RGDf(NMe)V). This peptide was then dubbed Cilengitide and is currently developed as drug by the company Merck-Serono (Germany). This article describes the chemical development of Cilengitide, the biochemical background of its activity and a short review about the present clinical trials. The positive anti-angiogenic effects in cancer treatment can be further increased by combination with “classical” anti-cancer therapies. Several clinical trials in this direction are under investigation.
Export Options
About this article
Cite this article as:
Mas-Moruno Carlos, Rechenmacher Florian and Kessler Horst, Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/187152010794728639
DOI https://dx.doi.org/10.2174/187152010794728639 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Actions of Polyhalogenated Arylhydrocarbons (PAHs) in Female Reproduction
Current Medicinal Chemistry RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target Signature Predictions
Combinatorial Chemistry & High Throughput Screening Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Entropy and Enthalpy in the Activity of Tubulin-Based Antimitotic Agents
Current Chemical Biology Possible Involvement of Angiogenesis in Chronic Liver Diseases: Interaction Among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress
Current Medicinal Chemistry Role of Muscarinic Acetylcholine Receptors in Breast Cancer: Design of Metronomic Chemotherapy
Current Clinical Pharmacology Effect of Short-term Quercetin, Caloric Restriction and Combined Treatment on Age-related Oxidative Stress Markers in the Rat Cerebral Cortex
CNS & Neurological Disorders - Drug Targets Nutritional Targeting of Cyclooxygenase-2 for Colon Cancer Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Polycistronic Viral Vectors
Current Gene Therapy Meet Our Editorial Board Member
Current Chemical Biology A Novel Sequence-Based Method for Phosphorylation Site Prediction with Feature Selection and Analysis
Protein & Peptide Letters Antioxidant, Anti-Inflammatory and Cytotoxic Properties of <i>Centaurea africana</i> Lamk var. [Bonnet] M
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry NSAIDs Induced Regulation of Alternatively Spliced Transcript Isoforms: Possible Role in Cancer and Alzheimer Disease
Current Cancer Drug Targets Targeting Aurora Kinases in Cancer Treatment
Current Drug Targets Cell-penetrating Peptide-based Intelligent Liposomal Systems for Enhanced Drug Delivery
Current Pharmaceutical Biotechnology Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells
Current Pharmaceutical Design CENPA a Genomic Marker for Centromere Activity and Human Diseases
Current Genomics Cyclometalated Complexes of Platinum and Gold with Biological Properties: State-of-the-Art and Future Perspectives
Current Medicinal Chemistry Synthesis, Cytotoxic and Heparanase Inhibition Studies of 5-oxo-1-arylpyrrolidine-3- carboxamides of Hydrazides and 4-amino-5-aryl-4H-1,2,4-triazole-3-thiol
Current Organic Synthesis